Table 2.
Clinical trial updates on Ayurveda, extract, and herbal medicine for the management of COVID-19. (https://clinicaltrials.gov/).
| S. No. | Title of Trial | Phase | Status | Conditions | NCT Number | Location |
|---|---|---|---|---|---|---|
| 1. | Ayurveda as preventive therapy for people suspected of having COVID-19. | Not applicable | No recruitment yet | COVID-19 | NCT04395976 | United Kingdom |
| 2. | Traditional Chinese medicines for the treatment of severe COVID-19. | Phase III | No recruitment yet | COVID-19 | NCT04323332 | China |
| 3. | Prevention & treatment of COVID-19 using traditional Chinese medicines. | Not applicable | Recruiting | Human Coronavirus causing Pneumonia | NCT04251871 | China |
| 4. | Patients with rheumatoid arthritis who take anti-rheumatic medications show an increased chance of contracting the COVID-19 infection. | - | Enrolling by invitation | ➢Rheumatoid arthritis ➢COVID-19 |
NCT04434118 | Egypt |
| 5. | Yinhu Qingwen decoction for treating moderate COVID-19. | Phase II Phase III | Suspended | ➢COVID-19 ➢Chinese medicine |
NCT04278963 | China |
| 6. | COVID distinction in accordance with traditional Chinese medicines, as well as a treatment procedure. | - | Completed | COVID-19 | NCT04306497 | China |
| 7. | YinhuQingwengranula to mitigate the effects of severe COVID-19. | Phase II, Phase III | Suspended | ➢COVID-19 ➢Severe Pneumonia ➢Chinese medicines |
NCT04310865 | China |
| 8. | A randomized controlled experiment to investigate the effectiveness of Lianhua Qingwen as adjuvant therapy in individuals who were reported with moderate symptoms of COVID-19. | Phase III | No recruitment yet | COVID 19 | NCT04433013 | - |
| 9. | A description of telehealthcare based on Chinese herbal medicine for the treatment of symptoms associated with viral illnesses such as COVID-19. | - | Recruiting | SARS-CoV-2 infection | NCT04380870 | United States |
| 10. | Hesperidin & Diosmin as a potential therapy for COVID-19. | Early phase I | No recruitment yet | Coronavirus infection | NCT04452799 | - |
| 11. | A survey on individual experiences with the traditional Chinese medication Jing-Guan-Fang for the treatment and prevention of COVID-19. | - | Recruiting | Coronavirus infection | NCT04388644 | Taiwan |
| 12. | The trial against COVID-19 using Honey & Nigella sativa. | Phase III | Recruiting | SARS-CoV-2 infection | NCT04347382 | Pakistan |
| 13. | Colchicine and phenolic monoterpenes have been shown to be effective in treating COVID-19. | Phase I Phase II | Recruiting | COVID 19 | NCT04392141 | Iran |
| 14. | Potential use of gum Arabic as an immune-modulating drug in individuals diagnosed with COVID-19. | Phase II Phase III | No recruitment yet | COVID 19 | NCT04381871 | Sudan |
| 15. | Colchicine in moderate symptomatic COVID-19 patients. | Not applicable | Recruiting (new) | COVID 19 | NCT04527562 | Bangladesh |
| 16. | Evaluation of the effectiveness & safety of Guduchi Ghan Vati in asymptomatic COVID-19 patients. | - | Completed | COVID 19 asymptomatic condition | NCT04480398 | India |
| 17. | Self-management using Ayurvedic techniques for flu- like symptoms throughout the COVID-19 epidemic. | Not applicable | Completed | COVID 19 flu-like symptom flu-like illness | NCT04345549 | United Kingdom |
| 18. | Ayurveda treatment for flu-like symptoms during the COVID-19 epidemic. | Not applicable | Completed | COVID-19 flu-like illness | NCT04351542 | United Kingdom |
| 19. | Providing protection to healthcare workers during the COVID-19 epidemic. | - | Completed | COVID-19 | NCT04387643 | India |
| 20. | The effect of combining therapy with the capsules of reginmune and the tablets of immuno free on the management of COVID-19 in patients with mild to moderate symptoms. | Phase II Phase III | Recruiting (new) | Treatment of Covid-19 virus infection | NCT04494204 | India |
| 21. | Lessons learnt from COVID-19: The goal of the TOMEKA® campaign is to educate. | - | No recruitment yet | COVID-19 | NCT04424940 | Congo |
| 22. | In asymptomatic COVID-19 patients, the use of phytomedicines as an additional treatment to Azithromycin compared with the use of hydroxychloroquine. | Phase II | Enrolling by invitation (new) | COVID-19 | NCT04501965 | Guinea |